161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC).
Saved in:
| Title: | 161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC). |
|---|---|
| Authors: | Veenstra, D.L.1 (AUTHOR), Hendrix, N.2 (AUTHOR), Dolan, C.M.3 (AUTHOR), Fisher, K.A.3 (AUTHOR), Lalla, D.4 (AUTHOR), Oestreicher, N.5 (AUTHOR), Moy, B.6 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS430-S431. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.08.442 |
